Novel bile acid therapeutics for the treatment of chronic liver diseases

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Fibrates and cholestasis

(2015) Nisanne S. Ghonem et al.   HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis

(2015) Alla Y. Grigorian et al.   Clinics and Research in Hepatology and Gastroenterology

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment

(2015) Brian P. Lam et al.   Therapeutic Advances in Gastroenterology

Fibroblast growth factor 15 deficiency impairs liver regeneration in mice

(2014) Bo Kong et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes

(2014) Bertrand Cariou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

(2014) Willem J. Lammers et al.   GASTROENTEROLOGY

The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice

(2014) TinaMarie Lieu et al.   GASTROENTEROLOGY

FXR, intestinal FiXeR of hepatocellular carcinoma?

(2014) Frank G. Schaap et al.   HEPATOLOGY

O135 INHIBITION OF INTESTINAL BILE ACID ABSORPTION BY ASBT INHIBITOR A4250 PROTECTS AGAINST BILE ACID-MEDIATED CHOLESTATIC LIVER INJURY IN MICE

(2014) A. Baghdasaryan et al.   JOURNAL OF HEPATOLOGY

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

(2014) F. Nevens et al.   JOURNAL OF HEPATOLOGY

FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation

(2014) Jun Yao   WORLD JOURNAL OF GASTROENTEROLOGY

PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis

(2014) Xueyan Zhou et al.   Nature Communications

Non-alcoholic fatty liver disease

(2014) N. Sattar et al.   BMJ-British Medical Journal

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

(2013) Emina Halilbasic et al.   Clinics in Liver Disease

Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice

(2013) Iker Uriarte et al.   GUT

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

The TGR5 receptor mediates bile acid–induced itch and analgesia

(2013) Farzad Alemi et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice

(2013) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages

(2013) Katrin Haselow et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Liver disease in the UK: a Lancet Commission

(2013) Roger Williams et al.   LANCET

Bile acid receptors as targets for drug development

(2013) Frank G. Schaap et al.   Nature Reviews Gastroenterology & Hepatology

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

(2013) Yongjie Ma et al.   PHARMACEUTICAL RESEARCH

Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice

(2012) Lisheng Zhang et al.   HEPATOLOGY

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer

(2012) Yanjun Jiang et al.   HEPATOLOGY

Nuclear Receptors HNF4α and LRH-1 Cooperate in RegulatingCyp7a1 in Vivo

(2012) Serkan Kir et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model

(2012) Ulrich Deuschle et al.   PLoS One

Primary biliary cirrhosis and bile acids

(2012) Christophe Corpechot   Clinics and Research in Hepatology and Gastroenterology

Fibroblast Growth Factor 19 Treatment Ameliorates Disruption of Hepatic Lipid Metabolism in Farnesoid X Receptor (Fxr)-Null Mice

(2011) Masaaki Miyata et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway

(2011) Matthew J. Potthoff et al.   Cell Metabolism

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

A biliary HCO3−umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes

(2011) Simon Hohenester et al.   HEPATOLOGY

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− (Abcb4 −/− ) mouse cholangiopathy model by promoting biliary HCO 3− output

(2011) Anna Baghdasaryan et al.   HEPATOLOGY

SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts

(2011) Barbara Renga et al.   INFLAMMATION RESEARCH

28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC

(2011) K.V. Kowdley et al.   JOURNAL OF HEPATOLOGY

The G Protein-Coupled Bile Acid Receptor, TGR5, Stimulates Gallbladder Filling

(2011) Tingting Li et al.   MOLECULAR ENDOCRINOLOGY

Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease

(2010) Raffaella M. Gadaleta et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Farnesoid X receptor modulators: a patent review

(2010) Matthew Lantz Crawley   EXPERT OPINION ON THERAPEUTIC PATENTS

Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis

(2010) N. Beraza et al.   GUT

Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist

(2010) G. Rizzo et al.   MOLECULAR PHARMACOLOGY

The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling

(2010) Kristine A. Drafahl et al.   PLoS One

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)

(2010) X. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts

(2009) Peter Fickert et al.   AMERICAN JOURNAL OF PATHOLOGY

TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis

(2009) Charles Thomas et al.   Cell Metabolism

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

(2009) Emina Halilbasic et al.   HEPATOLOGY

Diagnosis and management of primary sclerosing cholangitis

(2009) Roger Chapman et al.   HEPATOLOGY

Primary biliary cirrhosis

(2009) Keith D. Lindor et al.   HEPATOLOGY

FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation

(2009) Xinle Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

(2009)   JOURNAL OF HEPATOLOGY

Bile acid transporters

(2009) Paul A. Dawson et al.   JOURNAL OF LIPID RESEARCH

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice

(2009) Helen B. Hartman et al.   JOURNAL OF LIPID RESEARCH

Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity

(2009) Roberto Pellicciari et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

(2009) Brenton Flatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bile acids: Chemistry, physiology, and pathophysiology

(2009) Maria J Monte et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Expression and function of the bile acid receptor TGR5 in Kupffer cells

(2008) Verena Keitel et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Hereditary diffuse gastric cancer associated with E-cadherin mutation: penetrance after all

(2008) Daniel R. Gaya et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

(2008) Yan-Dong Wang et al.   HEPATOLOGY

The organic solute transporter  - , Ost -Ost , is essential for intestinal bile acid transport and homeostasis

(2008) A. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intestinal bile acid physiology and pathophysiology

(2008) Olga Martínez-Augustin et al.   WORLD JOURNAL OF GASTROENTEROLOGY